Danaher (NYSE:DHR) Price Target Raised to $250.00 at The Goldman Sachs Group

Danaher (NYSE:DHR) had its price target hoisted by The Goldman Sachs Group from $210.00 to $250.00 in a research note released on Monday. The firm currently has a buy rating on the conglomerate’s stock.

Several other analysts also recently weighed in on DHR. UBS Group initiated coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target for the company. DZ Bank initiated coverage on Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target on the stock. Stifel Nicolaus decreased their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Finally, Citigroup initiated coverage on Danaher in a report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $230.23.

Danaher Trading Up 0.3%

DHR stock opened at $221.80 on Monday. The stock has a market capitalization of $155.92 billion, a price-to-earnings ratio of 39.40, a price-to-earnings-growth ratio of 2.75 and a beta of 0.78. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The firm’s fifty day simple moving average is $205.26 and its two-hundred day simple moving average is $192.29. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, analysts anticipate that Danaher will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DHR. EP Wealth Advisors LLC acquired a new stake in shares of Danaher in the second quarter worth approximately $3,807,000. Puzo Michael J purchased a new position in Danaher in the 2nd quarter valued at $8,624,000. Madison Asset Management LLC acquired a new stake in Danaher during the 2nd quarter worth $85,451,000. First Nebraska Trust Co acquired a new stake in shares of Danaher in the second quarter valued at about $14,106,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Danaher in the second quarter worth about $11,800,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.